Comparative Pharmacology
Head-to-head clinical analysis: JEVTANA KIT versus TAXOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JEVTANA KIT versus TAXOL.
JEVTANA KIT vs TAXOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JEVTANA KIT contains cabazitaxel, a microtubule inhibitor that promotes tubulin assembly and stabilizes microtubules, leading to G2/M cell cycle arrest and apoptosis.
Paclitaxel stabilizes microtubules by binding to the β-tubulin subunit, preventing depolymerization, thereby disrupting mitotic spindle formation, cell division, and intracellular transport.
60 mg/m² IV over 1 hour every 3 weeks in combination with oral prednisone 10 mg daily continuously.
Intravenous infusion of 175 mg/m² over 3 hours every 3 weeks for ovarian carcinoma; 135 mg/m² over 24 hours every 3 weeks for breast carcinoma; 100 mg/m² over 3 hours every 2 weeks for NSCLC; 175 mg/m² over 3 hours every 2 weeks for AIDS-related Kaposi sarcoma.
None Documented
None Documented
Clinical Note
moderateBetaxolol + Digoxin
"Betaxolol may increase the bradycardic activities of Digoxin."
Clinical Note
moderateBetaxolol + Digitoxin
"Betaxolol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateBetaxolol + Deslanoside
"Betaxolol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateBetaxolol + Acetyldigitoxin
"Betaxolol may increase the bradycardic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 95 hours (range 34–266 hours), supporting a prolonged dosing interval of every 3 weeks.
Terminal elimination half-life is approximately 5.3 to 16.3 hours (mean ~13 hours); exhibits triphasic elimination with a prolonged terminal phase due to extensive tissue binding.
Primarily biliary/fecal: ~75% of dose recovered in feces as unchanged drug and metabolites; renal excretion accounts for <5% of the dose.
Primarily hepatic metabolism via CYP2C8 and CYP3A4; biliary/fecal excretion accounts for ~70% of total clearance; renal excretion is minimal (<10% as unchanged drug).
Category C
Category C
Taxane Antineoplastic
Taxane Antineoplastic